6-K 1 a3151d.htm RESULT OF AGM a3151d
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of May 2026
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Issued: 6 May 2026, London UK
 
Results of 26th Annual General Meeting
 
 
 
GSK plc ('GSK') held a hybrid Annual General Meeting ('AGM') at 2.30pm on Wednesday 6 May 2026 at the London Marriott Hotel Grosvenor Square, Grosvenor Square, London, W1K 6JP. Shareholders were able to join the meeting in person or virtually via the Lumi Global website and Zoom.
 
All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.
 
All 25 resolutions were passed and decided upon by a poll. The table below shows the results for each resolution. The full text of the resolutions is contained in the Notice of AGM published on 25 March 2026, which is available on GSK's website at www.gsk.com.
 
Resolution
Total votes for(1)(2)
%
Total votes against(2)
%
Total votes cast
% of Issued Share Capital voted(3)
Votes withheld(4)
1
Receive and adopt the 2025 Annual Report
3,073,839,952
99.25
23,182,191
0.75
3,097,022,143
76.38%
8,652,004
2
Approve the Annual report on remuneration 
2,986,046,185
96.74
100,644,457
3.26
3,086,690,642
76.12%
18,986,231
3
Approve the Remuneration policy
3,066,582,993
98.96
32,182,945
1.04
3,098,765,938
76.42%
6,914,570
4
Election of Luke Miels
3,081,325,569
99.37
19,501,818
0.63
3,100,827,387
76.47%
4,845,132
5
Re-election of Sir Jonathan Symonds
3,079,744,123
99.32
21,127,306
0.68
3,100,871,429
76.47%
4,793,341
6
Re-election of Julie Brown
3,069,722,312
99.00
31,102,814
1.00
3,100,825,126
76.47%
4,848,203
7
Re-election of Elizabeth McKee Anderson
3,042,023,812
98.52
45,732,363
1.48
3,087,756,175
76.15%
17,906,882
8
Re-election of Charles Bancroft
3,070,002,110
99.43
17,646,639
0.57
3,087,648,749
76.15%
18,018,954
9
Re-election of Dr Hal Barron
3,080,985,163
99.37
19,595,495
0.63
3,100,580,658
76.47%
5,088,510
10
Re-election of Dr Anne Beal
3,048,091,490
98.71
39,715,257
1.29
3,087,806,747
76.15%
17,858,160
11
Re-election of Wendy Becker
3,031,625,476
98.18
56,091,438
1.82
3,087,716,914
76.15%
17,946,122
12
Re-election of Dr Harry C Dietz
3,094,560,703
99.80
6,160,152
0.20
3,100,720,855
76.47%
4,943,572
13
Re-election of Dr Jeannie Lee
3,095,593,233
99.84
5,084,831
0.16
3,100,678,064
76.47%
4,985,598
14
Re-election of Dr Gavin Screaton
3,095,403,626
99.83
5,240,337
0.17
3,100,643,963
76.47%
5,019,966
15
Re-election of Dr Vishal Sikka
3,095,036,695
99.82
5,513,088
0.18
3,100,549,783
76.47%
5,111,280
16
Re-appointment of the auditor
3,099,113,772
99.94
1,891,083
0.06
3,101,004,855
76.48%
4,664,323
17
Remuneration of the auditor
3,098,976,181
99.94
1,736,335
0.06
3,100,712,516
76.47%
4,949,197
18
Authority for the company to make donations to political organisations and incur political expenditure
3,039,847,574
98.91
33,534,985
1.09
3,073,382,559
75.80%
32,288,122
19
Authority to allot shares
2,999,108,776
96.74
100,960,760
3.26
3,100,069,536
76.45%
5,592,295
20
Disapplication of pre-emption rights - general power(5)
3,046,584,734
98.32
51,962,919
1.68
3,098,547,653
76.42%
7,072,535
21
Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment(5)
3,059,992,748
98.75
38,710,772
1.25
3,098,703,520
76.42%
6,947,940
22
Authority for the company to purchase its own shares(5)
3,093,867,095
99.82
5,669,416
0.18
3,099,536,511
76.44%
6,127,609
23
Exemption from statement of senior statutory auditor's name
3,079,861,236
99.81
5,739,421
0.19
3,085,600,657
76.10%
20,038,163
24
Authority for reduced notice of a general meeting other than an AGM(5)
2,911,856,203
93.98
186,503,587
6.02
3,098,359,790
76.41%
7,285,017
25
Approve the amended Articles of Association(5)
3,065,959,469
99.40
18,375,929
0.60
3,084,335,398
76.07%
21,304,284
 
 
Notes:
 
(1)      The "for" votes include those giving the Chair discretion.
(2)      Votes "for" and "against" are expressed as a percentage of the total votes cast.
(3)      The Company's issued share capital as at 1 May 2026 consisted of 4,054,826,603 shares of 31 ¼ pence each ('Ordinary Shares') excluding Ordinary Shares held in Treasury. Every shareholder has one vote for every
           Ordinary Share held.
(4)      A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.
(5)      Indicates Special Resolutions requiring a 75% majority of votes cast.
 
 
The following table provides further information on participation in the AGM:
 
 
GSK's 26th AGM
(Hybrid meeting)
(2026)
GSK's 25th AGM
(Hybrid meeting)
(2025)
Issued share capital (excluding Treasury Shares)
4,054,826,603
4,109,037,095
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)
76.59%
74.21%
Total shareholder population
55,305
57,405
Total number of proxies lodged
2,475
2,617
Number of shareholders in attendance
117 in person
17 participated virtually
130 in person
25 participated virtually
% of shareholders who lodged proxies
4.48%
4.56%
 
The above poll results will shortly be available on the company's website at www.gsk.com.
 
In accordance with Listing Rule 6.4.2 of the Financial Conduct Authority's (FCA) Listing Rules, a copy of the resolutions, other than those concerning ordinary business, will be submitted to the FCA and will, in due course, be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
 
 
V A Whyte
Company Secretary
6 May 2026
 
 
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
 
 
Registered in England & Wales:
 
No. 3888792
 
 
Registered Office:
 
79 New Oxford Stree
 
London
 
WC1A 1DG
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: May 06, 2026
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
 behalf of GSK plc